Biofrontera Inc.

Biofrontera Inc. operates within the biopharmaceutical industry, focusing on the development and commercialization of dermatological medical treatments. Primarily known for its work in photodynamic therapy, Biofrontera offers solutions for skin conditions including actinic keratosis, which is a pre-cancerous skin condition. The company's flagship product, Ameluz, is an FDA-approved drug that is used in conjunction with a specialized lamp to effectively target and treat affected skin areas. Biofrontera's innovations impact the healthcare sector, specifically contributing to advancements in dermatological care and photodynamic treatment technologies. With a research-driven approach, the company plays a significant role in providing accessible skin disease treatments, potentially decreasing future cases of more severe conditions like skin cancer. Biofrontera is instrumental in enhancing patient outcomes through improved therapeutic strategies and remains a notable player in advancing dermal healthcare solutions globally. Headquartered in Germany, with a substantial presence in the U.S. market, Biofrontera Inc. continues to expand its footprint in dermo-pharmaceuticals, reinforcing its position in this specialized segment of the life sciences industry.